Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
Milja Heikkinen, Heidi Taipale, Antti Tanskanen, et al.
Addiction (2021) Vol. 116, Iss. 8, pp. 1990-1998
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder
Augustin Vannier, Jessica E.S. Shay, Vladislav Fomin, et al.
JAMA Network Open (2022) Vol. 5, Iss. 5, pp. e2213014-e2213014
Open Access | Times Cited: 87
Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge
Eden Y. Bernstein, Travis P. Baggett, Shrunjal Trivedi, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e243387-e243387
Open Access | Times Cited: 16
Alcoholic cardiomyopathy: an update
Fernándo Domínguez, Eric Adler, Pablo García‐Pavía
European Heart Journal (2024) Vol. 45, Iss. 26, pp. 2294-2305
Open Access | Times Cited: 16
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder
Markku Lähteenvuo, Jari Tiihonen, Anssi Solismaa, et al.
JAMA Psychiatry (2024)
Closed Access | Times Cited: 11
Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
Chia‐Chih Kuo, Chun‐Hsien Li, Min‐Hsiang Chuang, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 1
Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study
Ida Kim Wium‐Andersen, Marie Kim Wium‐Andersen, Anders Fink‐Jensen, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 131, Iss. 5, pp. 372-379
Open Access | Times Cited: 33
Inpatient Addiction Medicine Consultation Service Impact on Post-discharge Patient Mortality: a Propensity-Matched Analysis
J. Deanna Wilson, Stefanie C Altieri Dunn, Payel Roy, et al.
Journal of General Internal Medicine (2022) Vol. 37, Iss. 10, pp. 2521-2525
Open Access | Times Cited: 30
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder
Sophie Köhne, Thomas Hillemacher, Alexander Glahn, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 219-232
Closed Access | Times Cited: 7
Antidepressants, relapse-prevention medications and both combined to reduce alcohol-related hospitalizations in individuals with severe alcohol use disorder
Patrick Bach, Johan Franck, Jonas Hällgren, et al.
European Archives of Psychiatry and Clinical Neuroscience (2025)
Open Access
Pharmacological Treatments in Alcohol Use Disorder and Risk of Alcohol‐Related Hospitalizations: A Register Study
Patrick Bach, Johan Franck, Jonas Hällgren, et al.
Acta Psychiatrica Scandinavica (2025)
Open Access
Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung
Johanna Seifert, Stefan Bleich, Roland Seifert
Springer eBooks (2025), pp. 485-535
Closed Access
Psychotropic medication use pre and post-diagnosis of cluster B personality disorder: a Quebec’s health services register cohort
Carlotta Lunghi, Lionel Cailhol, Victoria Massamba, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 7
Estimating the prevalence of alcohol-related disorders and treatment utilization in Bremen 2016/2017 through routine data linkage
Justin Möckl, Christina Lindemann, Jakob Manthey, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 6
The use of medications approved for alcohol use disorders in Italy
Filomena Fortinguerra, Andrea Pierantozzi, Francesco Trotta
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 6
Can alcohol consumption in Germany be reduced by alcohol screening, brief intervention and referral to treatment in primary health care? Results of a simulation study
Jakob Manthey, Adriana Solovei, Peter Anderson, et al.
PLoS ONE (2021) Vol. 16, Iss. 8, pp. e0255843-e0255843
Open Access | Times Cited: 12
Racial and ethnic differences in self‐reported barriers to substance use treatment among emergency department patients
N. Jia Ahmad, Hannah Shapiro, Margaret L. Griffin, et al.
American Journal on Addictions (2024) Vol. 33, Iss. 6, pp. 631-640
Closed Access | Times Cited: 1
Patient Perspectives on Pharmacotherapy of Alcohol Dependence
Julian Wellensiek, Michael Specka, Johannes Just, et al.
Pharmacopsychiatry (2023) Vol. 57, Iss. 01, pp. 21-29
Closed Access | Times Cited: 2
Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis
N. Hashimoto, H Habu, Soshi Takao, et al.
Drug and Alcohol Dependence (2022) Vol. 233, pp. 109365-109365
Closed Access | Times Cited: 4
Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder
Benjamin Higginbotham, Joahna Kevin Perez, Eva Louie, et al.
Australian & New Zealand Journal of Psychiatry (2023) Vol. 58, Iss. 2, pp. 117-133
Open Access | Times Cited: 2
Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact
Kirsten C. Morley
Addiction (2021) Vol. 116, Iss. 11, pp. 3027-3028
Open Access | Times Cited: 5
Clustering care pathways of people with alcohol dependence using a data linkage of routine data in Bremen, Germany
Justin Möckl, Jakob Manthey, Monika Murawski, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access
Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis
Christopher Oldroyd, Jonathan Wood, Michael Allison
BMJ Open Gastroenterology (2024) Vol. 11, Iss. 1, pp. e001654-e001654
Open Access
The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder
Kamila Khikhmetova, Yuliya Semenova, Geir Bjørklund
Current Medicinal Chemistry (2023) Vol. 31, Iss. 39, pp. 6393-6406
Closed Access | Times Cited: 1
Response to "Alcohol and COVID-19: How Do We Respond to This Growing Public Health Crisis?”
Eileen Barrett, Krystle D. Apodaca
Journal of General Internal Medicine (2021) Vol. 36, Iss. 8, pp. 2476-2476
Open Access | Times Cited: 3
Extended‐release naltrexone for people with alcohol use disorder on therapeutic anticoagulation: A case series
Katrina Ciraldo, Manuel Seraydarian, James J. Gasper, et al.
Journal of Clinical Pharmacy and Therapeutics (2022) Vol. 47, Iss. 12, pp. 2393-2396
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top